Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 49 people enrolled
- Started
- 15 Apr 2018
- Ended
- 28 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Active rTMS
- Sham rTMS
- Record updated
- 28 January 2026
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- The study will be open to male and females, regardless of race and ethnic origin, who are in active treatment for an alcohol use disorder (AUD)
- Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for AUD, and alcohol is self-identified as primary substance of misuse
- Actively in treatment at VA Palo Alto HCS Addiction Treatment Service, and able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participation in study procedures
- Participants will be accepted if taking medications specifically for the treatment of MDD, cigarette smoking, or for other psychiatric conditions; as long as the medications are not documented to lower seizure threshold; must be stable on any psychotropic medication for at least 1 month prior to enrollment; it would be clinically contraindicated to require participants to discontinue such medications for research
- Participants will be abstinent from alcohol and non-prescribed substances for at least 7 consecutive days prior to active or sham rTMS and no participant demonstrates active acute withdrawal symptoms
Who cannot take part
- Current use of an FDA approved medication for treatment of AUD, i.e.:; disulfiram; acamprosate; naltrexone
- Active current suicidal intent or plan; patients with a previous clinical flag for risk for suicide will be required to have an established safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial
- Any form of previous rTMS or electroconvulsive treatment; Biomedical:
- Other severe cardiac illness as defined by treatment regimen changes in the prior 3 months
- Any biomedical implants with ferromagnetic content
- Psychiatric:
- History of Schizophrenia Spectrum Disorders
- Bipolar Disorders
- A current substance use disorder that exceeds the severity of the AUD; based on DSM-5 diagnostic criteria
- Including but not limited to uncontrolled thyroid disease
- Unstable congestive heart failure
- Angina
- Cancer if < 1 year since end of treatment
- Unstable diabetes
- Alzheimer's disease
- Parkinson's disease
- Cardiac pacemakers or any magnetic resonance contraindications
- Any primary or traumatically induced seizure disorder; General:
- Wechsler Adult Reading Test below the 7th percentile, i.e.:; moderate or greater impairment in estimated general intelligence
- Current use of any medication or substance that is documented to lower seizure threshold or has been identified as a contraindication for rTMS treatment
- Cerebrovascular accident
- COPD requiring oxygen supplementation
- Neurostimulation devices
- Traumatic brain injury with self-reported or observed loss of consciousness > 30 minutes
- Lack of fluency in English
- Females who are pregnant or actively attempting pregnancy; conservative exclusion for magnetic resonance research
Where in United States
- VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, United States
About the trial
What the trial wants to find out
At least 60% of Veterans with an alcohol use disorder will relapse within 6 months of treatment, irrespective of the type of treatment they receive. This indicates that currently available interventions for treating AUD in Veterans are not effective in helping them achieve long-term sobriety. Repetitive transcranial magnetic stimulation (rTMS) is a brain stimulation method that is at the forefront of innovative, non-invasive, and safe treatments for AUD. However, there have been no studies that specifically determined the effectiveness of rTMS treatment for Veterans with AUD. This project will evaluate the effectiveness of rTMS treatment in promoting long-term abstinence in Veterans suffering from AUD. Assisting Veterans in achieving long-term and sustained sobriety is critical because it is associated with the best medical, cognitive, psychiatric, and psychosocial recovery from AUD.
The 2 groups in the trial
- active rTMSExisting treatment, for comparison
Active rTMS will receive an intermittent rTMS stimulation protocol.
- sham rTMSSham treatment, for comparison
Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Leadership Styles Experienced During Military Service Predict Later Anhedonic Depressive Symptoms and Self-Efficacy in Veterans With Alcohol Use Disorder.Military medicine, 2024
- BDNF rs6265 Met carriers with alcohol use disorder show greater age-related decline of N-acetylaspartate in left dorsolateral prefrontal cortex.Drug and alcohol dependence, 2023
- Record updated
- 28 January 2026